Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chathuri Abeyakoon

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Expert Review of Hematology|June 25, 2024
Optimizing salvage therapy for Hodgkin lymphoma: progress and future challengesChathuri Abeyakoon, John Kuruvilla
Haematologica|April 2, 2026
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PROChathuri Abeyakoon, John Kuruvilla
British Journal of Haematology|January 22, 2024
New standards of care for treatment of diffuse large B-cell lymphomaChathuri Abeyakoon, Gareth P Gregory
Journal of Personalized Medicine|June 2, 2021
Targeted Approaches to T-Cell LymphomaSean Harrop, Chathuri Abeyakoon, Carrie Van Der Weyden, et al.
Expert Opinion on Pharmacotherapy|April 28, 2026
Innovative approaches for managing relapsed or refractory peripheral T-cell lymphomaBrian T Grainger, Joshua Casan, Chathuri Abeyakoon, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2021
Advances in Frontline Management of Peripheral T-cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Cancers|October 29, 2020
Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
International Journal of Molecular Sciences|July 29, 2025
Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell LymphomaCostas Kleanthes Yannakou, Simon Wu, Karthik Rajah, et al.
Critical Care (London, England)|July 5, 2023
Definitions of massive transfusion in adults with critical bleeding: a systematic reviewVictor S Lin, Emily Sun, Serine Yau, et al.
Blood Neoplasia|October 28, 2025
Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapyChathuri Abeyakoon, Sita Bhella, Katrina Hueniken, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Expert Review of Hematology|June 25, 2024
Optimizing salvage therapy for Hodgkin lymphoma: progress and future challengesChathuri Abeyakoon, John Kuruvilla
Haematologica|April 2, 2026
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PROChathuri Abeyakoon, John Kuruvilla
British Journal of Haematology|January 22, 2024
New standards of care for treatment of diffuse large B-cell lymphomaChathuri Abeyakoon, Gareth P Gregory
Journal of Personalized Medicine|June 2, 2021
Targeted Approaches to T-Cell LymphomaSean Harrop, Chathuri Abeyakoon, Carrie Van Der Weyden, et al.
Expert Opinion on Pharmacotherapy|April 28, 2026
Innovative approaches for managing relapsed or refractory peripheral T-cell lymphomaBrian T Grainger, Joshua Casan, Chathuri Abeyakoon, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2021
Advances in Frontline Management of Peripheral T-cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
Cancers|October 29, 2020
Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell LymphomaChathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, et al.
International Journal of Molecular Sciences|July 29, 2025
Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell LymphomaCostas Kleanthes Yannakou, Simon Wu, Karthik Rajah, et al.
Critical Care (London, England)|July 5, 2023
Definitions of massive transfusion in adults with critical bleeding: a systematic reviewVictor S Lin, Emily Sun, Serine Yau, et al.
Blood Neoplasia|October 28, 2025
Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapyChathuri Abeyakoon, Sita Bhella, Katrina Hueniken, et al.
Pageof 2